Burgess A V, Story B J, La D, Wagner W R, LeGeros J P
SULZERMEDICA, Sulzer Calcitek Inc., Carlsbad, California 92008, USA.
Clin Oral Implants Res. 1999 Aug;10(4):245-56. doi: 10.1034/j.1600-0501.1999.100401.x.
A novel pressurized hydrothermal post-plasma-spray process, referred to as MP-1, has been developed to convert the crystalline non-HA and amorphous components of plasma-sprayed hydroxylapatite coating back into crystalline HA. No detrimental effects are observed on the strength of either the base metal or the coating. X-ray diffraction (XRD) and FTIR analysis, surface roughness, shear adhesion strength and calcium solubility testing were conducted on Calcitite coated samples before and after treatment with this process. Other commercially available coatings were also studied using XRD and solubility testing. Quantitative XRD data show that the MP-1 treatment increases the average crystalline HA content of the Calcitite coating from 77% to 96%, while the amorphous content decreases from 21% to 4%. Other commercially available dental implant coatings ranged in crystalline HA content from 45% to 73%, with amorphous phase content ranging from 29% to 62%. FTIR spectra for treated coatings were significantly more well defined, and showed an increase in peak separation and intensity. Surface roughness and shear adhesion strength were not affected by the treatment. In vitro solubility testing revealed that for all coatings there is an initial introduction of calcium into solution over the first 2 h of testing; however, the amount of calcium dissolved was significantly lower for the MP-1 coating. Under a pH and temperature representative of normal physiologic conditions, the rate of calcium dissolution for the MP-1 coating was significantly lower than that of the other commercial HA coatings. In increasingly acidic conditions, the MP-1 coating was compared to the Calcitite coating and was found to have a significantly slower rate of calcium release. The MP-1 treatment enhances typical HA coatings by increasing the crystalline HA content at the expense of the plasma-spray-induced soluble phases without a reduction in the strength of the coating. The resulting coatings exhibit significantly decreased in vitro solubility over a wide range of pH. The results of this solubility testing suggest that the treated coating may show significantly enhanced in vivo stability, even under the extreme conditions encountered during periods of infection or rigorous detoxification procedures. The significant differences between plasma-sprayed HA coatings reported here underscore the need for industry and academic researchers to raise the level of discourse and understanding of HA coatings. By offering consistent and accurate descriptions of coating compositions and methods of analysis, meaningful comparisons between different HA coatings can be made.
一种新型的加压水热后等离子喷涂工艺,称为MP-1,已被开发出来,用于将等离子喷涂羟基磷灰石涂层中的结晶非HA和无定形成分转化回结晶HA。未观察到对母材或涂层强度有任何有害影响。对经过该工艺处理前后的Calcitite涂层样品进行了X射线衍射(XRD)和傅里叶变换红外光谱(FTIR)分析、表面粗糙度、剪切粘附强度和钙溶解度测试。还使用XRD和溶解度测试对其他市售涂层进行了研究。定量XRD数据表明,MP-1处理使Calcitite涂层的平均结晶HA含量从77%增加到96%,而无定形含量从21%降至4%。其他市售牙科植入物涂层的结晶HA含量在45%至73%之间,无定形相含量在29%至62%之间。处理后涂层的FTIR光谱定义明显更清晰,峰分离和强度增加。表面粗糙度和剪切粘附强度不受该处理的影响。体外溶解度测试表明,对于所有涂层,在测试的前2小时内都有钙最初进入溶液;然而,MP-1涂层溶解的钙量明显更低。在代表正常生理条件的pH值和温度下,MP-1涂层的钙溶解速率明显低于其他市售HA涂层。在酸性越来越强的条件下,将MP-1涂层与Calcitite涂层进行比较,发现其钙释放速率明显更慢。MP-1处理通过增加结晶HA含量,以牺牲等离子喷涂诱导的可溶相为代价,增强了典型的HA涂层,而不会降低涂层的强度。所得涂层在很宽的pH范围内表现出显著降低的体外溶解度。这种溶解度测试的结果表明,即使在感染或严格解毒程序期间遇到的极端条件下,处理后的涂层在体内的稳定性也可能显著提高。这里报道的等离子喷涂HA涂层之间的显著差异突出了行业和学术研究人员提高对HA涂层的讨论和理解水平的必要性。通过提供一致且准确的涂层成分描述和分析方法,可以对不同的HA涂层进行有意义的比较。